PDF(Pubmed)
Abstract：
BACKGROUND: The immune response dynamics in COVID-19 patients remain a subject of intense investigation due to their implications for disease severity and treatment outcomes. We examined changes in leukocyte levels, eosinophil activity, and cytokine profiles in patients hospitalized with COVID-19.
METHODS: Serum samples were collected within the first 10 days of hospitalization/confirmed infection and analyzed for eosinophil granule proteins (EGP) and cytokines. Information from medical records including comorbidities, clinical symptoms, medications, and complete blood counts were collected at the time of admission, during hospitalization and at follow up approximately 3 months later.
RESULTS: Serum levels of eotaxin, type 1 and type 2 cytokines, and alarmin cytokines were elevated in COVID-19 patients, highlighting the heightened immune response (p < 0.05). However, COVID-19 patients exhibited lower levels of eosinophils and eosinophil degranulation products compared to hospitalized controls (p < 0.05). Leukocyte counts increased consistently from admission to follow-up, indicative of recovery.
CONCLUSIONS: Attenuated eosinophil activity alongside elevated chemokine and cytokine levels during active infection, highlights the complex interplay of immune mediators in the pathogenesis COVID-19 and underscores the need for further investigation into immune biomarkers and treatment strategies.
METHODS: Serum samples were collected within the first 10 days of hospitalization/confirmed infection and analyzed for eosinophil granule proteins (EGP) and cytokines. Information from medical records including comorbidities, clinical symptoms, medications, and complete blood counts were collected at the time of admission, during hospitalization and at follow up approximately 3 months later.
RESULTS: Serum levels of eotaxin, type 1 and type 2 cytokines, and alarmin cytokines were elevated in COVID-19 patients, highlighting the heightened immune response (p < 0.05). However, COVID-19 patients exhibited lower levels of eosinophils and eosinophil degranulation products compared to hospitalized controls (p < 0.05). Leukocyte counts increased consistently from admission to follow-up, indicative of recovery.
CONCLUSIONS: Attenuated eosinophil activity alongside elevated chemokine and cytokine levels during active infection, highlights the complex interplay of immune mediators in the pathogenesis COVID-19 and underscores the need for further investigation into immune biomarkers and treatment strategies.
摘要：
背景：由于COVID-19患者的免疫反应动力学对疾病严重程度和治疗结果的影响，因此仍然是一个需要深入研究的主题。我们检查了白细胞水平的变化，嗜酸性粒细胞活性，和COVID-19住院患者的细胞因子谱。
方法：在住院/确诊感染的前10天内收集血清样本，并分析嗜酸性粒细胞颗粒蛋白（EGP）和细胞因子。来自医疗记录的信息，包括合并症，临床症状,药物,在入院时收集完整的血细胞计数，住院期间和大约3个月后的随访期间.
结果：血清eotaxin水平，1型和2型细胞因子，COVID-19患者的Alarmin细胞因子升高，突出了增强的免疫应答(p<0.05)。然而,与住院对照组相比，COVID-19患者的嗜酸性粒细胞和嗜酸性粒细胞脱颗粒产物水平较低(p<0.05)。白细胞计数从入院到随访持续增加，预示着复苏。
结论：在活动性感染期间，嗜酸性粒细胞活性减弱，趋化因子和细胞因子水平升高，强调了免疫介质在COVID-19发病机制中的复杂相互作用，并强调需要进一步研究免疫生物标志物和治疗策略。
方法：在住院/确诊感染的前10天内收集血清样本，并分析嗜酸性粒细胞颗粒蛋白（EGP）和细胞因子。来自医疗记录的信息，包括合并症，临床症状,药物,在入院时收集完整的血细胞计数，住院期间和大约3个月后的随访期间.
结果：血清eotaxin水平，1型和2型细胞因子，COVID-19患者的Alarmin细胞因子升高，突出了增强的免疫应答(p<0.05)。然而,与住院对照组相比，COVID-19患者的嗜酸性粒细胞和嗜酸性粒细胞脱颗粒产物水平较低(p<0.05)。白细胞计数从入院到随访持续增加，预示着复苏。
结论：在活动性感染期间，嗜酸性粒细胞活性减弱，趋化因子和细胞因子水平升高，强调了免疫介质在COVID-19发病机制中的复杂相互作用，并强调需要进一步研究免疫生物标志物和治疗策略。
